July 2012

Dear Shareholders,

For the first six months of 2012, we introduced the CRH Medical story to dozens of investors, analysts and bankers. In July, we focused on solidifying these relationships. The majority of the professionals we’ve met over the past several months have shown a significant interest in the Company and have communicated to us that they intend to become more engaged as our business grows.

To help facilitate our growth, we’ve been working on several new initiatives behind the scenes in July.

Recently, we partnered with a number of gastroenterology practices in several markets across the United States to create direct-to-consumer TV commercials that highlight the efficacy and safety of the CRH O’Regan System as the gold standard for hemorrhoid treatment.

Please click the link below to view a sample of one of the commercials.

http://youtu.be/TzWTpLqH5N8

This past month, we have also been focussed on the production of a new consumer awareness video, which we believe will generate greater awareness for our patented, single use O’Regan System. The video is on track to premiere on our website sometime in August; we will include a link to it in our next Investor Bulletin.

We are keenly aware that CRH Medical’s website (www.crhmedcorp.com) is an important source of information for investors, physicians and patients. As such, we have been working diligently on a new design and hope to launch this more visually compelling and interactive site in August or September.

Focus on current and new market opportunities

Next month, we will be attending the GI Outlook meeting in Chicago to raise our profile with thought leaders in gastroenterology

As a growth story, we are also continuously evaluating new market opportunities for the O’Regan System and in July, we set our sights on general surgeons in the United States.

This market segment, from a commercial perspective, has a significant upside for CRH Medical. Many general surgeons are active in the surgical treatment of hemorrhoids, and, because of the O’Regan System’s relative ease of use, we feel that many would be receptive to a new and better way to treat the condition.

However, unlike the gastroenterologist market – where the lion’s share of our revenue comes from – the general surgeon market opportunity is fragmented.

At this point, the risk/reward profile to try and gain ground with this group seems favourable but it will take time before we reach any conclusions about making a significant investment in the pursuit of this market segment. We will update you on this endeavour as we move forward.

We look forward to sharing the August edition of the CRH Investor Bulletin with you next month, and as always, we appreciate your interest and support.

 

Sincerely,

Adam Peeler, Media and Investor Relations
TMX Equicom
416.815.0700 x 225
apeeler@equicomgroup.com

We're a stable, profitable company respected by both patients and physicians. Learn more »